3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
fludarabine
10
Specimen Handling
8
Cytarabine
8
Cyclophosphamide
8
Biopsy
8
fludarabine phosphate
7
Whole-Body Irradiation
7
venetoclax
6
Injections
6
Busulfan
6
Azacitidine
6
Mycophenolic Acid
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
decitabine and cedazuridine drug combination
4
X-Rays
4
Tacrolimus
4
Stem Cell Transplantation
4
Cyclosporine
4
CPX-351
4
Peripheral Blood Stem Cell Transplantation
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Decitabine
3
treosulfan
2
ruxolitinib
2
luspatercept
2
ivosidenib
2
gilteritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
durvalumab
×
30 days
×
Clear all
No trials found.